Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs MyDrHank

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and MyDrHank head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 70 · Grade C

MyDrHank

Visit MyDrHank Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 74 on our six-factor Brief Score — The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make MyDrHank a bad call — it's best for readers who already intend to prepay a year up front and want one account covering glp-1 alongside nad+, sermorelin and four other lines — and who will check the term attached to a price before treating it as a monthly bill. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
80
Supply Reliability
95
78
Transparency
90
62
Access Breadth
93
76
Clinical Oversight
92
74
Track Record
88
72
CoreAge RxBrief Score 94 · 74MyDrHank

Price, coverage & the tracker

CoreAge RxMyDrHank
Brief Score94/100 (A)74/100 (C)
Semaglutide$99/mo$259/mo (month-to-month; prepay tiers lower)
Tirzepatide$149/mo$349/mo (month-to-month; prepay tiers lower)
CoverageAll 50 states44 states (not KS, LA, MS, NM, ND, WV)
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

MyDrHank: First reading. The funnel advertises "from $240" tirzepatide and "from $171" semaglutide; both are twelve-month prepay rungs, and the month-to-month rates — $349 and $259 — appear on no page of it.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.